2012
Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high‐dose granulocyte colony‐stimulating factor
Cooper DL, Proytcheva M, Medoff E, Seropian SE, Snyder EL, Krause DS, Wu Y. Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high‐dose granulocyte colony‐stimulating factor. Journal Of Clinical Apheresis 2012, 27: 235-241. PMID: 22566214, DOI: 10.1002/jca.21232.Peer-Reviewed Original ResearchConceptsHigh-dose G-CSFAutologous HPC transplantationHematopoietic progenitor cellsG-CSFHPC transplantationProgenitor cellsAutologous peripheral blood progenitor cell collectionHigh-dose granulocyte colony-stimulating factorAutologous peripheral blood progenitor cellsRetrospective medical record reviewPeripheral blood progenitor cell collectionPeripheral blood progenitor cellsMedical record reviewGranulocyte-colony stimulating factorGranulocyte colony-stimulating factorBlood progenitor cellsEfficacy of mobilizationProgenitor cell harvestsProgenitor cell collectionColony-stimulating factorPlatelet engraftmentRecord reviewSafety profileGood mobilizersPeripheral blood
2003
A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents
Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplantation 2003, 32: 1113-1117. PMID: 14647264, DOI: 10.1038/sj.bmt.1704286.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCombined Modality TherapyCyclophosphamideDatabases, FactualDexamethasoneDoxorubicinFemaleFeverGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansLeukapheresisMaleMiddle AgedMultiple MyelomaNeutropeniaPeripheral Blood Stem Cell TransplantationRetrospective StudiesTransplantation, AutologousVincristineConceptsMultiple myelomaEnough stem cellsCells/Autologous stem cell rescueFever/neutropeniaG-CSF beginningStem cell rescueHigh-dose chemotherapyPotential transplant candidatesMultiple myeloma patientsStem cell collectionStem cell toxicityStem cellsAggressive chemotherapyInitial therapyTransplant candidatesAgent therapyConsecutive patientsExcessive morbidityMyeloma patientsCell mobilizationCell rescuePatientsG-CSFCell collection
2001
Xenotransplantation of immunodeficient mice with mobilized human blood CD34+ cells provides an in vivo model for human megakaryocytopoiesis and platelet production
Perez L, Rinder H, Wang C, Tracey J, Maun N, Krause D. Xenotransplantation of immunodeficient mice with mobilized human blood CD34+ cells provides an in vivo model for human megakaryocytopoiesis and platelet production. Blood 2001, 97: 1635-1643. PMID: 11238102, DOI: 10.1182/blood.v97.6.1635.Peer-Reviewed Original ResearchConceptsPeripheral blood stem cellsHuman peripheral blood stem cellsPlatelet productionVivo modelStudy of megakaryocytopoiesisCFU-MKHuman megakaryocytopoiesisImmunodeficient miceBone marrowHuman plateletsExogenous cytokinesNOD/SCID miceHuman hematopoiesisBlood stem cellsHuman cell engraftmentPlatelet developmentNonobese diabetic/Lymphoid lineageStem cellsHuman blood CD34MegakaryocytopoiesisPeripheral bloodCytokine stimulationMurine recipientsThrombin stimulation
1999
A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells
Burtness B, Psyrri A, Rose M, D’Andrea E, Staugaard-Hahn C, Henderson-Bakas M, Clark M, Mechanic S, Krause D, Snyder E, Cooper R, Abrantes J, Corringham R, Deisseroth A, Cooper D. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplantation 1999, 23: 311-315. PMID: 10100573, DOI: 10.1038/sj.bmt.1701589.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CD34Antineoplastic Agents, PhytogenicBlood Cell CountHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHumansInfusions, IntravenousMiddle AgedPaclitaxelConceptsSchedule of paclitaxelDose escalationH infusionPeripheral blood progenitor cellsDose of paclitaxelPhase I trialBlood progenitor cellsStem cell yieldStem cellsTolerable toxicityI trialInfusion scheduleDose levelsPhase IPaclitaxelDoseProgenitor cellsCells/NeuropathyFilgrastimInfusionEscalation
1998
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study
Chabannon C, Cornetta K, Lotz J, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau J, Sledge G, Novakovitch G, Srour E, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. British Journal Of Cancer 1998, 78: 913-921. PMID: 9764583, PMCID: PMC2063121, DOI: 10.1038/bjc.1998.601.Peer-Reviewed Original ResearchConceptsPoor prognosis breast cancerHigh-dose chemotherapyHaematopoietic recoveryBreast cancerRecombinant human granulocyte colony-stimulating factorBlood cellsRandomized multicentre studyGranulocyte colony-stimulating factorHuman granulocyte colony-stimulating factorPeripheral blood cellsPeripheral blood CD34Peripheral blood progenitorsColony-stimulating factorMobilized blood cellsEpithelial tumor cellsEligible patientsStudy armsMulticentre studyPeripheral bloodConventional chemotherapyStudy groupPatientsChemotherapyBlood CD34CD34Cytosine Deaminase Adenoviral Vector and 5-Fluorocytosine Selectively Reduce Breast Cancer Cells 1 Million-Fold When They Contaminate Hematopoietic Cells: A Potential Purging Method for Autologous Transplantation
Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine Deaminase Adenoviral Vector and 5-Fluorocytosine Selectively Reduce Breast Cancer Cells 1 Million-Fold When They Contaminate Hematopoietic Cells: A Potential Purging Method for Autologous Transplantation. Blood 1998, 92: 672-682. PMID: 9657770, DOI: 10.1182/blood.v92.2.672.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsAntimetabolites, AntineoplasticBreast NeoplasmsCell DeathCytosine DeaminaseFemaleFlucytosineFluorouracilGene Transfer TechniquesGenetic VectorsHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHumansMaleMiceNucleoside DeaminasesProdrugsTransplantation, AutologousTumor Cells, CulturedConceptsBreast cancer cellsPeripheral blood mononuclear cellsBreast cancer patientsCancer patientsCytosine deaminase geneHuman mammary epithelial cellsAdenoviral vectorCancer cellsHours of exposureHematopoietic cellsAutologous stem cell productsMarrow cellsEscherichia coli cytosine deaminase geneReplication-incompetent adenoviral vectorEpithelial cellsChemotherapy-induced myelosuppressionBreast cancer cell line MCF-7Blood mononuclear cellsEarly hematopoietic precursor cellsMale donor miceCancer cell line MCF-7Fluorescence-activated cell sorting (FACS) analysisMCF-7 breast cancer cellsNormal human mammary epithelial cellsMDA-MB-453